0836 GMT - U.K. pharma could have some share-price volatility but the long-term outlook shouldn't be affected by U.S. President Trump's imposed tariffs on global imports that currently exempt drugs and vaccines, Shore Capital analyst Sean Conroy says in a note. The longer-term revenue targets for British pharma companies GSK and AstraZeneca extend beyond the remaining term of Trump and their fundamentals remain robust as populations are getting older and sicker, the analyst says. "Pharma often finds itself in the firing line when it comes to U.S. politics--given the prominence of drug prices on the U.S. political agenda and news cycle--however, more often than not there is a material difference between traveling and arriving, with the impact realized often far less draconian than initially feared," he says. GSK and AstraZeneca are both up 1.5% and 1.6%, respectively. (helena.smolak@wsj.com)
(END) Dow Jones Newswires
April 03, 2025 04:36 ET (08:36 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。